CYLD

AcronymDefinition
CYLDCylindromatosis, Familial
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
Mutations in the CYLD gene in BrookeSpiegler syndrome, familial cylindromatosis, and multiple familial trichoepithelioma: lack of genotype-phenotype correlation.
Beyaert, "CYLD, A20 and OTULIN deubiquitinases in NF-[kappa]B signaling and cell death: so similar, yet so different," Cell Death and Differentiation, vol.
This is now recognized as a variant form of Brooke-Spiegler syndrome (spiradenoma, cylindroma, and trichoepithelioma) caused by germline mutation in the CYLD gene.
Szell, "Phenotype-genotype correlations for clinical variants caused by CYLD mutations," European Journal of Medical Genetics, vol.
Mosialos, "Activation of peroxisome proliferator-activated receptor gamma in mammary epithelial cells upregulates the expression of tumor suppressor Cyld to mediate growth inhibition and anti-inflammatory effects," The International Journal of Biochemistry & Cell Biology, vol.
For example, CYLD inhibits osteoclastogenesis via downregulating RANK signaling [99].
miR-362 targeted cylindromatosis (CYLD) activation of the NF-kB pathway induced cell growth and apoptosis tolerance in gastric cancer.
Thus, deubiquitinating enzymes such as A20 and CYLD are negative regulators of NOD-signaling pathways and pro-inflammatory cytokine responses are markedly increased in A20-deficient or CYLD-deficient APCs upon stimulation with NOD ligand.
Other cases are caused by mutations of the cylindromatosis oncogene (CYLD) which maps to 16/q12-q13.2 This is an autosomal dominant disorder with less penetrance in men so mainly expressed in females.
Genes Tested AtP ALK APC ATM BAP1 BRCA2 BRIP1 BUB1B CDC73 CDH1 CEP57 CHEK2 CYLD DDB2 DICER1 ERCC3 ERCC4 ERCC5 EXT1 EXT2 FANCD2 FANCE FANCF FANCG FANCI GATA2 GPC3 HNF1A HOXB13 HRAS MLH1 MHS2 MSH6 MUTYH NBN PHOX2B PMS1 PMS2 PPM1D PRF1 RAD51D RBI RECQL4 RET RHBDF2 SDHC SDHD SLX4 SMAD4 SMARCA4 TP53 TSC1 TSC2 VHL WT1 BARD1 BLM BMPR1A BRCA1 CDK4 CDKN1C CDKN2A CEBPA DI53L2 EGFR EPCAM ERCC2 EZH2 FANCA FANCB FANCC FANCL FANCM FH FLCN KIT MAX MEN1 MET NF1 NF2 NSD1 PALB2 PRKAR1A PTCH1 PTEN RAD51C RUN XI SBDS SDHAF2 SDHB SMARCB1 STK11 5UFU TMEM127 WRN XPA XPC This chart shows all 98 cancer susceptible genes included in this new test.
We showed that when SPL is silenced in mouse embryonic fibroblasts, extracellular S1P activates STAT3 through an S1PR1-dependent pathway, resulting in decreased expression of the antioncogene CYLD, a negative regulator of NF[kappa]B [147] (Figure 4).
TRAF6 is targeted by a number of inhibitory molecules such as Tumour Necrosis Factor Inducible Protein A20 (A20), Ubiquitin Specific Peptidase 4 (USP4), Ubiquitin-SpecificProcessing Protease CYLD (CYLD), TRAF Family Member Associated NF-[kappa]B Activator (TANK), Tripartite Motif Containing Protein 38 (TRIM38), and Small Heterodimer Partner (SHP) [96-98].